ClinicalTrials.Veeva

Menu

Vitamin D Supplementation in Glomerular Disease

Children's Hospital of Philadelphia (CHOP) logo

Children's Hospital of Philadelphia (CHOP)

Status

Completed

Conditions

Glomerular Disease

Treatments

Dietary Supplement: Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT01835639
12-009753
K23DK093556 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

This multi-site, pilot study will assess vitamin D supplementation in children and young adults with Glomerular Disease. .

Full description

Vitamin D deficiency has been linked to a variety of adverse health outcomes. Nephrotic patients have very low vitamin D levels, and the underlying mechanisms are not known. Furthermore, approaches to safely and effectively supplement vitamin D in these patients have not been established. The purpose of this research study is to learn if vitamin D supplementation is safe and effective in patients with primary glomerular disease and to also help establish the treatment guidelines. About 35 patients with primary glomerular disease, ages 5-30 years old, will take part in this study. Participants will be asked to take vitamin D supplements each day for 12 weeks and will have 3 study visits.

Enrollment

32 patients

Sex

All

Ages

5 to 30 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Males or females, age 5-30 years
  • Diagnosis of primary glomerular disease (such as steroid-resistant nephrotic syndrome, minimal change disease, FSGS, membranous nephropathy, membranoprolfierative glomerulonephritis, and Immunoglobulin A [IgA] nephropathy) without systemic inflammatory disorders (i.e. lupus, vasculitis)
  • Serum 25(OH)D level <30 ng/ml and urine protein:creatinine ratio ≥0.5 at Screening Visit.

Exclusion criteria

  • Pregnancy
  • estimated Glomerular Filtration Rate (eGFR) <30 ml/min/1.73m2 at Screening Visit
  • Serum phosphorus > 5.5 mg/dl or hypercalcemia
  • Chronic medical conditions or medications unrelated to the renal disease that may impact vitamin D status
  • Known history of kidney stone(s)

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

32 participants in 1 patient group

Vitamin D Supplementation
Experimental group
Description:
Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks
Treatment:
Dietary Supplement: Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks

Trial contacts and locations

5

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems